Document Detail

Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.
MedLine Citation:
PMID:  19056295     Owner:  NLM     Status:  MEDLINE    
Prognosis of PTCL is generally poor when treated with conventional chemotherapy regimens used in B-cell aggressive lymphomas. Recent advances in genomic and molecular profiling of PTCL have allowed to further insight this heterogeneous group of neoplasias and their main prognostic factors. This review will try to summarize the main clinical problems related to standard frontline and salvage therapy, including the use of conventional chemotherapy and high-dose, dose-dense and immunotherapeutic strategies, as well as new approaches based on biological knowledge and the use of new drugs or immunotherapy.
J Rodríguez; A Gutiérrez; B Martínez-Delgado; G Perez-Manga
Related Documents :
22638885 - Intralymphatic delivery of platinum-based chemotherapeutics is possible: an experimenta...
3284695 - Relapsing large cell immunoblastic lymphoma complicating well-differentiated lymphocyti...
18647965 - Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and...
16847665 - Nodal marginal zone b-cell lymphoma: analysis of 36 cases. clinical presentation and tr...
11022825 - Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 p...
3882205 - Right hepatic lobectomy for primary and metastatic tumour: experience in a community te...
Publication Detail:
Type:  Journal Article; Review     Date:  2008-12-03
Journal Detail:
Title:  Critical reviews in oncology/hematology     Volume:  71     ISSN:  1879-0461     ISO Abbreviation:  Crit. Rev. Oncol. Hematol.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-03     Completed Date:  2009-10-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8916049     Medline TA:  Crit Rev Oncol Hematol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  181-98     Citation Subset:  IM    
Service of Oncology, General University Hospital Gregorio Marañon, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Chromosome Aberrations
Drug Delivery Systems / methods,  trends*
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genomics / methods
Immunotherapy / methods,  trends
Lymphoma, T-Cell, Peripheral / diagnosis,  genetics,  pathology*,  therapy*
Neoplasm Invasiveness
Stem Cell Transplantation / methods
Tumor Markers, Biological / antagonists & inhibitors*,  genetics
Reg. No./Substance:
0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mitral valve disease: if the mitral valve is not reparable/failed repair, is bioprosthesis suitable ...
Next Document:  Rationally designed peptide regulators of protein kinase C.